Status:
UNKNOWN
Shenfu Injection Improves Arterial Vascular Reactivity
Lead Sponsor:
Jianfeng Xie
Conditions:
Septic Shock
Shenfu
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
Septic shock is a common and critical illness in ICU.The vascular dysfunction of septic shock is manifested by vasospasm and decreased arterial vascular reactivity . Current studies have shown that th...
Eligibility Criteria
Inclusion
- diagnosed as septic shock according to 2016 SSC Guidelines;
- The dose of norepinephrine required to maintain MAP\>65mmHg ≥0.5μg/kg.min;
- SVRI \<800 dyns/cm5.m2;
- CI\>2.5L/min/m2;
- The patient or the patient's family signed the informed consent form for this trial.
Exclusion
- septic shock occurs more than 24 hours;
- Age \> 85 years old or \<18 years old;
- pregnant or lactating women;
- There are shock patients caused by other causes such as cardiogenicity and neurogenicity;
- The terminal state of malignant tumor end-stage disease or the patient who is expected to die within 24 hours.
Key Trial Info
Start Date :
December 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2019
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03749525
Start Date
December 1 2018
End Date
September 1 2019
Last Update
November 21 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.